Upload at 2019-02-27 16:20:57.307808
Sandra Spalek
CC BY 4.0
Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.
Number Nodes
Number Edges
Number Components
Network Density
Average Degree
Number Citations
Number BEL Errors

Content Statistics

Network Overlap

The node-based overlap between this network and other networks is calculated as the Szymkiewicz-Simpson coefficient of their respective nodes. Up to the top 10 are shown below.

Network Overlap
Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation v1.0.0 29%
Heme Curation v0.0.1-dev 21%
Tau protein aggregation is associated with cellular senescence in the brain v1.0.0 17%
Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice v1.0.0 17%
Inflammasome Involvement in Alzheimer’s Disease v1.0.0 8%
Clearance systems in the brain-implications for Alzheimer disease. v1.0.1 8%
Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) - a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease v1.0.0 8%
Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease v1.0.0 8%
Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis v1.0.0 8%
Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease v1.0.0 8%

Sample Edges

a(CHEBI:Anatabine) decreases a(MESH:Cytokines) View Subject | View Object

This particular dosage was selected from a previous study showing that this dosage is efficient at lowering brain cytokine levels in a mouse model of Alzheimer’s disease displaying chronic neuroinflammation PubMed:23383175

Alzheimer Disease

a(CHEBI:Anatabine) negativeCorrelation path(MESH:Encephalomyelitis) View Subject | View Object

Clinical signs of EAE became apparent by day 6 following the immunization in the placebo group but were delayed to day 11 in the anatabine treatment group (Fig. 1A) PubMed:23383175

a(CHEBI:Anatabine) decreases path(MESH:Encephalomyelitis) View Subject | View Object

The average clinical severity of EAE was also significantly reduced by the anatabine treatment (Fig. 1B) PubMed:23383175

a(CHEBI:Anatabine) decreases path(MESH:Paralysis) View Subject | View Object

Importantly, approximately 70% of the mice in the placebo group developed hind-limb weakness or paralysis compared to only 20% in the anatabine treatment group (Fig. 1C) showing that the mice treated with anatabine displayed significantly milder disease symptoms than the placebo group PubMed:23383175


Sample Nodes


BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.